ID: ALA5194085

Max Phase: Preclinical

Molecular Formula: C17H17ClN4O4

Molecular Weight: 376.80

Representations

Canonical SMILES:  Cc1ncnc2c1c(-c1ncccc1Cl)cn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O

Standard InChI:  InChI=1S/C17H17ClN4O4/c1-8-12-9(13-10(18)3-2-4-19-13)5-22(16(12)21-7-20-8)17-15(25)14(24)11(6-23)26-17/h2-5,7,11,14-15,17,23-25H,6H2,1H3/t11-,14-,15-,17-/m1/s1

Standard InChI Key:  RSYJRYYEXCZHJJ-BNGXUDDSSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 376.80

Molecular Weight (Monoisotopic): 376.0938

AlogP: 1.07

#Rotatable Bonds: 3

Polar Surface Area: 113.52

Molecular Species: NEUTRAL

HBA: 8

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.46

CX Basic pKa: 5.21

CX LogP: 0.51

CX LogD: 0.50

Aromatic Rings: 3

Heavy Atoms: 26

QED Weighted: 0.63

Np Likeness Score: 0.37

References

1. Lin C, Karalic I, Matheeussen A, Feijens PB, Hulpia F, Maes L, Caljon G, Van Calenbergh S..  (2022)  Exploration of 6-methyl-7-(Hetero)Aryl-7-Deazapurine ribonucleosides as antileishmanial agents.,  237  [PMID:35533570] [10.1016/j.ejmech.2022.114367]

Source

Source(1):

• Scientific Literature